![Shehnaaz Suliman](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Shehnaaz Suliman
Director/Board Member at
ULTRAGENYX PHARMACEUTICAL INC.
Net worth: 3 M $ as of 2026-08-30
Profile
Shehnaaz Suliman is currently President, Chief Executive Officer & Director at ReCode Therapeutics, Inc. since 2022.
She is Chief Executive Officer at Transcriptx, Inc. She serves as Chairman at Executive Women in Bio.
She is an Independent Director at 10X Genomics, Inc. and Ultragenyx Pharmaceutical, Inc., both since 2019.
Former roles include Director at Parvus Therapeutics, Inc. from 2017 to 2019, Vice President & Area Head-Global Therapeutic at Roche Holding AG from 2015 to 2017, Senior VP-Corporate Development & Strategy at Theravance Biopharma, Inc. from 2017 to 2019, and Chief Operating & Business Officer at Alector, Inc. from 2021 to 2022.
Education includes graduate and MBA degrees from the University of Oxford, and undergraduate and doctorate degrees from the University of Cape Town.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-08-23 | 29,515 ( 0.02% ) | 2 M $ | 2026-08-30 | |
| 2026-05-17 | 27,951 ( 0.03% ) | 704 645 $ | 2026-08-30 |
Shehnaaz Suliman active positions
| Companies | Position | Start |
|---|---|---|
| ULTRAGENYX PHARMACEUTICAL INC. | Director/Board Member | 2019-01-29 |
| 10X GENOMICS, INC. | Director/Board Member | 2019-07-31 |
Executive Women in Bio
 Executive Women in Bio Miscellaneous Commercial ServicesCommercial Services Provides mentoring program services that supports women in various career and personal development stages | Chairman | - |
ReCode Therapeutics, Inc.
 ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage genetic medicines company that develops therapeutics for genetically defined diseases | Chairman | 2026-06-30 |
Transcriptx, Inc.
 Transcriptx, Inc. BiotechnologyHealth Technology Develops mRNA therapies intended to treat primary ciliary dyskinesia | Chief Executive Officer | - |
Former positions of Shehnaaz Suliman
| Companies | Position | End |
|---|---|---|
| ALECTOR, INC. | Chief Executive Officer | 2021-12-14 |
Parvus Therapeutics, Inc.
 Parvus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells biopharmaceutical products | Director/Board Member | 2019-06-30 |
| THERAVANCE BIOPHARMA, INC. | Corporate Officer/Principal | 2019-03-30 |
| ROCHE HOLDING AG | Corporate Officer/Principal | 2017-06-30 |
Training of Shehnaaz Suliman
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
76
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Roche Holding AG
 Roche Holding AG Pharmaceuticals: MajorHealth Technology Operates as a research-focused healthcare company with combined focus in pharmaceuticals and diagnostics | Health Technology |
Ultragenyx Pharmaceutical, Inc.
 Ultragenyx Pharmaceutical, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel products for the treatment of serious rare and ultra-rare genetic diseases | Health Technology |
10X Genomics, Inc.
 10X Genomics, Inc. BiotechnologyHealth Technology Develops integrated systems and solutions for genome sequencing, exome sequencing and single cell transcriptomics | Health Technology |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Cape Town
 University of Cape Town Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Theravance Biopharma, Inc.
 Theravance Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of human therapeutics products for respiratory diseases | Health Technology |
Alector, Inc.
 Alector, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for Alzheimer’s disease and other neurodegenerative disorders | Health Technology |
ReCode Therapeutics, Inc.
ReCode Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage genetic medicines company that develops therapeutics for genetically defined diseases | Health Technology |
Parvus Therapeutics, Inc.
Parvus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells biopharmaceutical products | Health Technology |
Transcriptx, Inc.
Transcriptx, Inc. BiotechnologyHealth Technology Develops mRNA therapies intended to treat primary ciliary dyskinesia | Health Technology |
Executive Women in Bio
Executive Women in Bio Miscellaneous Commercial ServicesCommercial Services Provides mentoring program services that supports women in various career and personal development stages | Commercial Services |
- Stock Market
- Insiders
- Shehnaaz Suliman
